透雲生物(01332.HK)擬4000萬港元出售Genius Spring 90.10%股權
格隆匯10月29日丨透雲生物(01332.HK)公吿,於2021年10月29日,賣方恆優有限公司(公司的間接非全資附屬公司)與買方Planetree (BVI) Capital Limited訂立買賣協議,據此,賣方同意出售,而買方同意購買待售股份(佔出售公司Genius Spring Limited 90.10%的股權),代價為4000萬港元。
完成於簽署買賣協議時同時落實。於完成後,出售公司將不再為公司的非全資附屬公司,而其相關財務表現、資產及負債於出售事項後將不會於集團的綜合財務報表入賬。
公司認為出售事項為公司變現出售公司持有的證券投資的良機,並可降低近期股票市場波動的風險。此外,出售事項產生的現金所得款項將加強公司的流動資金資源。公司有意將出售事項的所得款項淨額用作一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.